FDA approves BeiGene's Brukinsa in rare blood cancer

seekingalpha2021-09-02

BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). WM is a type of cancer affecting two...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Nichktan
2021-09-02
Nichktan
Like and comment pls
- Moneyong:
  Ok
Sriwonc
2021-09-02
Sriwonc
Like pls
- Nichktan:
  Like and Comment pls
Jen88
2021-09-02
Jen88
Good
- Kelvinneo:
  okay
Heidit
2021-09-02
Heidit
Cool
- Jen88:
  Liked
alexcsb
2021-09-02
alexcsb
Biotech nowadays getting popular
- cHao7:
  huat
LIM97
2021-09-02
LIM97
like n comment
- Demong:
  Ok
- Heidit:
  Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1127321282?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-02 16:39","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1127321282","market":"us","top_or_hot":-1,"title":"FDA approves BeiGene's Brukinsa in rare blood cancer","media":"seekingalpha","content":"<div>\n<p>BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).\nWM is a type of cancer affecting two...</p>\n\n<a href=\"https://seekingalpha.com/news/3736525-fda-approves-beigenes-brukinsa-in-rare-blood-cancer\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves BeiGene's Brukinsa in rare blood cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves BeiGene's Brukinsa in rare blood cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736525-fda-approves-beigenes-brukinsa-in-rare-blood-cancer><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).\nWM is a type of cancer affecting two...</p>\n\n<a href=\"https://seekingalpha.com/news/3736525-fda-approves-beigenes-brukinsa-in-rare-blood-cancer\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BGNE","symbol_name":"百济神州","start_time":0,"source_url":"https://seekingalpha.com/news/3736525-fda-approves-beigenes-brukinsa-in-rare-blood-cancer","article_id":"1127321282","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127321282","pubTimestamp":1630571951,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatme","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BGNE":"百济神州"},"translate_title":"FDA批准百济神州Brukinsa用于罕见血癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":0.9},"content_text":"BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).\nWM is a type of cancer affecting two types of B cells: lymphoplasmacytoid cells and plasma cells. Both cell types are white blood cells.\nThe approval is primarily based on efficacy results from the Phase 3 ASPEN trial comparing BRUKINSA to ibrutinib in patients with WM.\n“We are delighted by today’s FDA approval for BRUKINSA in its second indication, offering a new treatment option with demonstrated efficacy and safety benefits for patients with Waldenström’s macroglobulinemia,\" commented Jane Huang, M.D., Chief Medical Officer, Hematology at BeiGene.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":812860138,"gmtCreate":1630573938424,"gmtModify":1631889119250,"author":{"id":"3567067978989911","authorId":"3567067978989911","name":"Nichktan","avatar":"https://static.tigerbbs.com/73a93daf14236dfaeabaf3ea0b82fe4d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3567067978989911","idStr":"3567067978989911"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812860138","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5729109,"gmtCreate":1630574851539,"gmtModify":1631889119253,"authorId":3575367895713518,"author":{"id":3575367895713518,"idStr":"3575367895713518","authorId":3575367895713518,"name":"Moneyong","avatar":"https://static.tigerbbs.com/310106f7833de54751b1a4f33ac43e61","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812860138,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":812884872,"gmtCreate":1630573700996,"gmtModify":1632472259541,"author":{"id":"3586424409701165","authorId":"3586424409701165","name":"Sriwonc","avatar":"https://static.tigerbbs.com/264a5cfcdc2db585d9b139a4c4d7b11d","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3586424409701165","idStr":"3586424409701165"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812884872","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5729019,"gmtCreate":1630573954893,"gmtModify":1635132906084,"authorId":3567067978989911,"author":{"id":3567067978989911,"idStr":"3567067978989911","authorId":3567067978989911,"name":"Nichktan","avatar":"https://static.tigerbbs.com/73a93daf14236dfaeabaf3ea0b82fe4d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812884872,"type":1,"supId":0,"prevId":0,"content":"Like and Comment pls","text":"Like and Comment pls","html":"Like and Comment pls"}],"langContent":"EN"},{"id":812814225,"gmtCreate":1630572797667,"gmtModify":1631889828883,"author":{"id":"3582993517958198","authorId":"3582993517958198","name":"Jen88","avatar":"https://static.tigerbbs.com/5aaf732b230f1241c2c9b76b2b27ae00","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3582993517958198","idStr":"3582993517958198"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812814225","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728901,"gmtCreate":1630573151673,"gmtModify":1631889828884,"authorId":3576527829922352,"author":{"id":3576527829922352,"idStr":"3576527829922352","authorId":3576527829922352,"name":"Kelvinneo","avatar":"https://static.tigerbbs.com/02f9dc9fba8b950702638da01ab252b8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812814225,"type":1,"supId":0,"prevId":0,"content":"<u>okay</u>","text":"<u>okay</u>","html":"<u>okay</u>"}],"langContent":"EN"},{"id":812812573,"gmtCreate":1630572667892,"gmtModify":1631893742439,"author":{"id":"3585567341976837","authorId":"3585567341976837","name":"Heidit","avatar":"https://static.tigerbbs.com/b15a14bcb1e7c71684448d84f3e500e7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3585567341976837","idStr":"3585567341976837"},"htmlText":"&nbsp;Cool&nbsp;","listText":"&nbsp;Cool&nbsp;","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812812573","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728852,"gmtCreate":1630572803902,"gmtModify":1631893742443,"authorId":3582993517958198,"author":{"id":3582993517958198,"idStr":"3582993517958198","authorId":3582993517958198,"name":"Jen88","avatar":"https://static.tigerbbs.com/5aaf732b230f1241c2c9b76b2b27ae00","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812812573,"type":1,"supId":0,"prevId":0,"content":"Liked","text":"Liked","html":"Liked"}],"langContent":"EN"},{"id":812818927,"gmtCreate":1630572468569,"gmtModify":1631891193530,"author":{"id":"3586915072418371","authorId":"3586915072418371","name":"alexcsb","avatar":"https://static.tigerbbs.com/b02b98b9a53bdc70b2b8955a1bb7db4f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586915072418371","idStr":"3586915072418371"},"htmlText":"Biotech nowadays getting popular&nbsp;","listText":"Biotech nowadays getting popular&nbsp;","text":"Biotech nowadays getting popular","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/812818927","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728863,"gmtCreate":1630572853529,"gmtModify":1631891193533,"authorId":3571630433284403,"author":{"id":3571630433284403,"idStr":"3571630433284403","authorId":3571630433284403,"name":"cHao7","avatar":"https://static.tigerbbs.com/3800b5d66328f3184368a219227b02a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812818927,"type":1,"supId":0,"prevId":0,"content":"<u>huat</u>","text":"<u>huat</u>","html":"<u>huat</u>"}],"langContent":"EN"},{"id":812811549,"gmtCreate":1630572433581,"gmtModify":1631893890525,"author":{"id":"3581419265926610","authorId":"3581419265926610","name":"LIM97","avatar":"https://static.tigerbbs.com/6e8b924a13e75ddd5dcb294949bced1f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581419265926610","idStr":"3581419265926610"},"htmlText":"like n comment","listText":"like n comment","text":"like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/812811549","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728835,"gmtCreate":1630572730632,"gmtModify":1631893890554,"authorId":3581632751482150,"author":{"id":3581632751482150,"idStr":"3581632751482150","authorId":3581632751482150,"name":"Demong","avatar":"https://static.tigerbbs.com/dbceb89832d6c8630b4f99a879c4878d","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812811549,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"},{"id":5728825,"gmtCreate":1630572662778,"gmtModify":1631893890530,"authorId":3585567341976837,"author":{"id":3585567341976837,"idStr":"3585567341976837","authorId":3585567341976837,"name":"Heidit","avatar":"https://static.tigerbbs.com/b15a14bcb1e7c71684448d84f3e500e7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812811549,"type":1,"supId":0,"prevId":0,"content":"Ok ","text":"Ok ","html":"Ok "}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":44,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127321282"}